Bioassay guided purification of the antimicrobial fraction of a Brazilian propolis from Bahia state

Myrella Lessio Castro1, Walquíria Ribeiro Vilela2, Rogéria Cristina Zauli2, Masaharu Ikegaki3, Vera Lúcia Garcia Rehder4, Mary Ann Foglio4, Severino Matias de Alencar2 and Pedro Luiz Rosalen*1

Address: 1Department of Physiological Sciences, Piracicaba Dental School, University of Campinas (UNICAMP); Avenida Limeira, 901; Piracicaba, SP, 13414-903, Brazil, 2Department of Agri-Food Industry, Food and Nutrition, Escola Superior de Agricultura “Luiz de Queiroz”, University of São Paulo (USP); Avenida Pádua Dias, 11; Piracicaba, SP, 13418-900, Brazil, 3Department of Pharmacy, Federal University of Alfenas, Alfenas, MG, Brazil; Avenida Gabriel Monteiro da Silva, 700; Alfenas, MG, 37130-000, Brazil and 4Chemical, Biological and Agricultural Pluridisciplinary Research Center (CPQBA), University of Campinas (UNICAMP); C.P. 6171; Campinas, SP, 13081-970, Brazil

Email: Myrella Lessio Castro - myrella@fop.unicamp.br; Walquíria Ribeiro Vilela - wal_vilela@yahoo.com.br; Rogéria Cristina Zauli - rogeriazauli@yahoo.com.br; Masaharu Ikegaki - masaharu@unifal-mg.edu.br; Vera Lúcia Garcia Rehder - rehder@cpqba.unicamp.br; Mary Ann Foglio - foglioma@cpqba.unicamp.br; Severino Matias de Alencar - alencar@esalq.usp.br; Pedro Luiz Rosalen* - rosalen@fop.unicamp.br

* Corresponding author

Published: 30 July 2009

BMC Complementary and Alternative Medicine 2009, 9:25 doi:10.1186/1472-6882-9-25

Received: 19 March 2009
Accepted: 30 July 2009

This article is available from: http://www.biomedcentral.com/1472-6882/9/25

© 2009 Castro et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

**Background:** Brazilian propolis type 6 (Atlantic forest, Bahia) is distinct from the other types of propolis especially due to absence of flavonoids and presence of other non-polar, long chain compounds, but presenting good in vitro and in vivo antimicrobial activity. Several authors have suggested that fatty acids found in this propolis might be responsible for its antimicrobial activity; however, so far no evidence concerning this finding has been reported in the literature. The goals of this study were to evaluate the antibacterial activity of the main pure fatty acids in the ethanolic extract and fractions and elucidate the chemical nature of the bioactive compounds isolated from Brazilian propolis type 6.

**Methods:** Brazilian propolis type 6 ethanolic extract (EEP), hexane fraction (H-Fr), major fatty acids, and isolated sub-fractions were analyzed using high performance liquid chromatography (HPLC), high resolution gas chromatography with flame ionization detection (HRGC-FID), and gas chromatography-mass spectrometry (GC-MS). Three sub-fractions of H-Fr were obtained through preparative HPLC. Antimicrobial activity of EEP, H-Fr, sub-fractions, and fatty acids were tested against *Staphylococcus aureus* ATCC 25923 and *Streptococcus mutans* Ingbritt 1600 using minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC).

**Results:** EEP and H-Fr inhibited the growth of the microorganisms tested; nevertheless, no antimicrobial activity was found for the major fatty acids. The three sub-fractions (1, 2, and 3) were isolated from H-Fr by preparative HPLC and only sub-fraction 1 showed antimicrobial activity.

**Conclusion:** a) The major fatty acids tested were not responsible for the antimicrobial activity of propolis type 6; b) Sub-fraction 1, belonging to the benzophenone class, was responsible for the antimicrobial activity observed in the present study. The identification of the bioactive compound will improve the development of more efficient uses of this natural product.
Background
Propolis, a non-toxic resinous hive product collected by Apis mellifera bees from various plant sources, has been reported to have several properties that may confer health benefits to humans since ancient times [1,2]. Propolis chemical composition and pharmacological activity might vary significantly depending on its geographic origin and seasonal effect [3-6]. Furthermore, its chemical composition is extremely complex and its flavonoids and (hydroxyl) cinnamic acid derivatives have been widely cited as its biologically active compounds [7-9]. Although these compounds have not been detected in propolis classified as type 6 (from the Atlantic forest, Northeastern Brazil) [10,11], its ethanolic extract and hexane fractions (H-Fr) have shown remarkable antimicrobial activities against pathogens, including mutans streptococci [11-13]. It has been proposed that the antimicrobial activity of type-6 propolis might be due to a high proportion of fatty acids (oleic, palmitic, linoleic, and stearic) identified as part of its chemical composition [13]; nonetheless, such compounds (fatty acids) have not been tested. Therefore, the goals of the present study were to evaluate the antibacterial activity of the main pure fatty acids found in the ethanolic extract and fractions of Brazilian propolis type 6, as well as to elucidate the chemical nature of the bioactive compounds isolated from it.

Methods
Propolis samples and fractionation
Crude samples of Apis mellifera propolis, originated from the Atlantic forest region, state of Bahia, SL 11°56'31 and WL 38°05'04, in the Northeastern Region of Brazil, classified as propolis type 6 [10] and botanically originated from Hyptis divaricata [3], were acquired in May 2006. The ethanolic extract of propolis (EEP) at 20% (w/v) was prepared using aqueous ethanol (80% v/v) according to the literature [13]. The EEP was further fractionated using a liquid-liquid extraction technique with hexane to generate a polar fraction (P-Fr) and H-Fr. The purification grade of the EEP, its fractions, and sub-fractions as described in the literature [16]. Aliquots of 400 μL (10 mg/mL) of the samples were placed into glass vials and 400 μL of CH3N2 were added to each solution. All the samples were refrigerated for 4 h to allow complete methylation and then analyzed by GC-MS using a CPB5 column (30 m × 0.25 mm i.d.) installed in a GC 17A (Shimadzu Co.) instrument interfaced with a QP 5000 mass selective detector operated in scanning mode (m/z 40-400). For GC-MS analysis, the temperature was set from 50°C (0.3 min hold) to 285°C (15 min hold) at a rate of 6°C/min. The samples were injected with an AOC-17 autoinjector using a splitless injection technique (0.6 μL injection volume) and He flow was set at 1.0 mL/min. The GC-MS peaks were identified by comparison with data found in the literature and characterized using the library search software of Shimadzu Class-Vp (Wiley 138 and Nist 98 databases).

Analytical and preparative HPLC analysis
A Shimadzu Prep 6AD LC system equipped with a SPD-M10Avp photodiode array detector (PDA), an auto injector 10AF, and a fraction collector FRC-10A, was used to perform the HPLC analysis. For the analytical test, diluted solutions of EEP, fractions (H-Fr and P-Fr), and isolated sub-fractions (1, 2, and 3) (1 mg/100 mL) were filtered (Millipore - 0.22 μm), and 10 μL aliquots were injected in a Shimadzu reverse-phase analytical column of 250 mm × 4.6 mm (i.d.) × 5 μm (particle size). For the mobile phase, we used water (solvent A) and methanol (solvent B) at a constant flow rate of 1 mL/min. The gradient started with 80-90% for solvent B at 15 min returning to 80% at 30 min. All sub-fractions were detected according to characteristic UV-vis spectra (spectral range of 200-450 nm) and retention times. Preparative HPLC was carried out using a preparative column Shimadzu PREP-ODS (H) (250 mm × 20 mm – i.d). To isolate the sub-fractions, a gradient using both solvents was used at room temperature with a flow rate of 8 mL/min [6]. Three sub-fractions were isolated from H-Fr.

High resolution gas chromatography with flame ionization detection (HRGC-FID)
Fatty acid methyl esters (FAMEs) were prepared from EEP, its fractions and sub-fractions according to a modification of the method by Hartman and Lago (1973) [15]. Samples of 0.3 μL were injected into a Hewlett-Packard (HP) 5890 series II gas chromatographer equipped with a 60 m DB-23 (0.25 mm I.D., 0.25 μm film thickness) column. The oven temperature was programmed as follows: 130°C (1.0 min) to 170°C (6.5°C/min), 170°C to 215°C (2.75°C/min), 215°C (12 min), 215°C to 230°C (40°C/min), and 230°C (3 min). The injector and detector were used at 270°C and 280°C, respectively. FAMEs were identified using standard of fatty acids (Sigma, St Louis, MO, USA) with 6, 8, 10, 12, 14, 15, 16 (cis e trans), 17, 18 (cis e trans), 20, 22, and 24 atoms of carbon, saturated and unsaturated and helium (He) was used as the carrier gas (1.0 mL/min).

Gas chromatography-mass spectrometry (GC-MS)
The analyses of fatty acid were performed after methylation of the EEP, its fractions, and sub-fractions as described in the literature [16]. Aliquots of 400 μL (10 mg/mL) of the samples were placed into glass vials and 400 μL of CH3N2 were added to each solution. All the samples were refrigerated for 4 h to allow complete methylation and then analyzed by GC-MS using a CBP5 column (30 m × 0.25 mm i.d.) installed in a GC 17A (Shimadzu Co.) instrument interfaced with a QP 5000 mass selective detector operated in scanning mode (m/z 40-400). For GC-MS analysis, the temperature was set from 50°C (0.3 min hold) to 285°C (15 min hold) at a rate of 6°C/min. The samples were injected with an AOC-17 autoinjector using a splitless injection technique (0.6 μL injection volume) and He flow was set at 1.0 mL/min. The GC-MS peaks were identified by comparison with data found in the literature and characterized using the library search software of Shimadzu Class-Vp (Wiley 138 and Nist 98 databases).
Microbial susceptibility testing

The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the EEP, fractions, pure fatty acids, and isolated sub-fractions were evaluated to determine their antimicrobial activity using *Streptococcus mutans* Ingbritt 1600 and *Staphylococcus aureus* ATCC 25923, based on previously published methodology [12,13]. To determine MIC we used inoculums of $5 \times 10^5$ CFU/mL, concentrations of EEP, fractions, and pure fatty acids ranging from 6.25 to 1600 $\mu$g/mL, and concentration of isolated sub-fractions ranging from 0.2 to 210 $\mu$g/mL. To determine MBC, aliquots of 20 $\mu$L of all incubated tubes with concentrations higher than the MIC were subcultured on BHI agar and supplemented with 5% defibrinated sheep blood using a spiral plater (Whitley Automatic Spiral Plater) [12]. All these analyses were performed in triplicate. We used ethanol (final ethanol concentration: 0.6%, v/v) as the control vehicle and digluconate chlorhexidine 0.12% (Sigma®) as positive control in both tests.

Table 1: Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of different fractions against *Staphylococcus aureus* ATCC 25923 and *Streptococcus mutans* Ingbritt 1600.

| Sample | Staphylococcus aureus ATCC 25923 | Streptococcus mutans Ingbritt 1600 |
|--------|---------------------------------|-----------------------------------|
|        | MIC ($\mu$g/mL) | MBC ($\mu$g/mL) | MIC ($\mu$g/mL) | MBC ($\mu$g/mL) |
| EEP    | 25–50             | 400–800            | 50–100           | > 1600          |
| H-Fr   | 25–50             | 200–400            | 50–100           | 800–1600        |
| P-Fr   | 50–100            | 400–800            | 100–200          | > 1600          |
| Positive Control* | 1.5–3.1       | 3.1–6.25          | 0.75–1.5         | 1.5–3.1         |

*Positive Control: digluconate chlorhexidine 0.12% – Sigma®. ND: not determined. Experiments carried out in triplicate.

Results and Discussion

Table 1 shows MIC and MBC values for EEP, H-Fr, and P-Fr, respectively. MIC values indicated that the H-Fr exhibited strong antibacterial activity against *S. aureus* and *S. mutans*, with concentrations as low as 25 $\mu$g/mL and 50 $\mu$g/mL, respectively. Similar results were found in other studies for *S. mutans* Ingbritt 1600 [12,13], but no data concerning antimicrobial activity of EEP and its fractions against *S. aureus* were available in the literature. The H-Fr showed lower values than the other samples and this finding indicated the presence of an active compound in this fraction. However, MIC and MBC values for EEP, H-Fr, and P-Fr were higher than that found for the positive control (chlorhexidine 0.12%). This might be explained by the fact that a synthetic pure mono-drug (chlorhexidine) was compared with the fractions of a natural product that presents its biological compound diluted in the samples (EEP, H-Fr, or P-Fr).

HPLC analyses of EEP and H-Fr demonstrated identical chemical profiles for both, since they presented three chemical peaks in common and in similar proportions (Figure 1) and neither flavonoids nor cinnamic acid derivatives were detected.

Figure 1

RP-HPLC Chromatograms of propolis type 6. (A) Ethanol extract of propolis (EEP) and (B) hexane fractions (H-Fr). Peaks 1, 2, and 3 have the same retention time in both A and B graphics.
by previous findings (Table 2) [12,13]. We identified the following fatty acids: oleic (18:1), palmitic (16:0), linoleic (18:2), and stearic (18:0), present in higher concentrations in EEP and H-Fr, as already shown in previous studies [12,13]. Based on previous studies showing similar results [17-19], some authors suggested that the chemical composition of this propolis might be responsible for its antimicrobial activity [12,13].

The same fatty acids (oleic, palmitic, linoleic, and stearic acid – Sigma®), tested isolatedly or mixed, showed no bacterial activity against Gram-positive bacteria (S. aureus or S. mutans) at concentrations lower than 1600 μg/mL. However, MIC values found for H-Fr were lower than 50 and 100 μg/mL for S. aureus and S. mutans, respectively (Table 1), suggesting that other compounds, different from the fatty acids tested, might account for the antimicrobial activity detected in the present study.

Since no satisfactory MIC and MBC results were found for the fatty acids tested, three unpurified sub-fractions were isolated from H-Fr by means of preparative HPLC and tested, isolatedly or mixed, for antibacterial activity. Only sub-fraction 1 (peak 1, Figure 1B) showed satisfactory antibacterial activity against S. aureus and S. mutans, with MIC ranging from 1.56 to 3.12 and 3.12 to 6.2 μg/mL, respectively (Table 3), but the mixture of these three sub-fractions showed no bacterial activity. This might have happened due to the dilution of the active compounds present in sub-fraction 1, thus excluding the possibility of any synergistic effects of these three sub-fractions.

MIC values found for sub-fraction 1 were similar to those obtained for the positive control (chlorhexidine 0.12%) for both microorganisms tested, suggesting that sub-fraction 1 might contain an antimicrobial bioactive compound. In addition, since chlorhexidine, a pure mono-drug, and sub-fraction 1, an impure bioactive compound, showed similar MIC results, we might speculate that this compound could be a promising antimicrobial agent, which needs to be isolated and identified. TLC and HPLC analyses of sub-fraction 1 showed a mixture of non-polar compounds; however, when sub-fraction 1 was analyzed by HRGC-FID, no fatty acid characteristics were found (Figure 2). Furthermore, when sub-fraction 1 was analyzed by PDA detector, two maximum absorbance values were found (240 nm and 300 nm), which is characteristic of benzophenone compounds [20,21]. GC-MS analyses showed fragments at m/z 105, indicating that this sub-fraction belongs to the benzophenone class and is not a fatty acid, as suggested in the literature [10,12,13]. Fragments at m/z 77, 69, and 55 showed its prenylated nature (Figure 3) and those at m/z 433 and 309 confirmed that this is a polyprenylated benzophenone [21].

Benzophenones are among the most important chemical compounds identified and isolated from propolis found in tropical regions [20-23]. They have been reported as

| Sample          | Staphylococcus aureus ATCC 25923 | Streptococcus mutans Ingbritt 1600 |
|-----------------|----------------------------------|-----------------------------------|
|                 | MIC (μg/mL)                      | MBC (μg/mL)                       | MIC (μg/mL) | MBC (μg/mL) |
| Sub-fraction 1  | 1.5–3.1                          | 26–53                             | 3.1–6.25    | 53–106      |
| Sub-fraction 2  | > 210                            | > 210                             | > 210       | > 210       |
| Sub-fraction 3  | > 210                            | > 210                             | > 210       | > 210       |
| Positive control*| 1.5–3.1                          | 3.1–6.25                          | 0.75–1.5    | 1.5–3.1     |

*Positive control: digluconate chlorhexidine 0.12% – Sigma®. Experiments carried out in triplicate.
having various biological activities, such as potential antimicrobial activity against both Gram-positive and Gram-negative bacteria [22-27].

**Conclusion**

No antimicrobial activity was observed for the main fatty acids identified in Brazilian propolis type 6. Sub-fraction 1 isolated from this type of propolis belongs to the benzophenone class and was responsible for the antimicrobial activity observed in the present study. The identification of this bioactive compound will improve the development of more efficient uses of this natural product.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

This study was conceived, directed, and coordinated by PLR and SMA, who also critically revised the manuscript with the help of MI. MLC participated throughout the study (chemical and microbiological assays). WR and RCZ worked in the preparation of the extracts, fractions, and analyses of fatty acids. VLR and MAF gave their support in the chromatography laboratory and helped interpret data. All the authors read and approved the final manuscript.

**Acknowledgements**

The authors thank FAPESP (Proc. No. 04/10992-1), CNPq (131758/2006-3), FAPEMIG (EDT-240/05), and Mr. José Elpidio de Mendonça Cerqueira, Naturapi – Produtos Naturais e Apícolas Ltda., for providing the propolis samples.

**References**

1. Ghisalberti EL: Propolis: a review. Bee World 1979, 60:59-84.
2. Burdock GA: Review of the biological properties and toxicity of bee propolis. Food Chem Toxicol 1998, 36:347-363.
3. Park YK, Alencar SM, Aguiar CL: Botanical origin and chemical composition of Brazilian propolis. J Agric Food Chem 2002, 50:2502-2506.
4. Bankova V: Recent trends and important developments in propolis research. Evid Based Complement Alternat Med 2005, 2:29-32.
5. Castro ML, Duarte S, Ikegaki M, Cury JA, Koo H, Alencar SM, Rosalen PL: Própolis do sudeste e nordeste do Brasil: influência da sazonalidade na atividade antibacteriana e composição fenólica. Quim Nova 2007, 30:1512-1516.
6. Alencar SM, Oldoni TLC, Castro ML, Cabral ISR, Costa-Neto CM, Cury JA, Rosalen PL, Ikegaki M: Chemical composition and biological activity of a new type of Brazilian propolis: red propolis. J Ethnopharmacol 2007, 113:278-283.
7. Koo H, Gomes BP, Rosalen PL, Ambrosano GM, Park YK, Cury JA: In vitro antimicrobial activity of propolis and Arnica montana against oral pathogens. Arch Oral Biol 2000, 45:141-148.
8. Bankova VS, Castro SL, Marcucci MC: Propolis: recent advances in chemistry and plant origin. Apidologie 2000, 31:3-15.
9. Marcucci MC, Ferreres F, Garcia-Vigueria C, Bankova VS, Castro SL, Dantas AP, Valette PHM, Paulino N: Phenolic compounds from Brazilian propolis with pharmacological activities. J Ethnopharmacol 2001, 74:105-112.
10. Park YK, Ikegaki M, Alencar SM, Moura FF: Evaluation of Brazilian propolis by both physicochemical methods and biological activity. Honeybee Sci 2000, 21:85-90.
11. Koo H, Rosalen PL, Cury JA, Ambrosano GMB, Murata RM, Yatsuda R, Ikegaki M, Alencar SM, Park YK: Effect of a new variety of Apis mellifera propolis on mutans streptococci. Curr Microbiol 2000, 41:192-196.
12. Duarte S, Koo H, Bowen WH, Hayacibara MF, Cury JA, Ikegaki M, Rosalen PL: Effect of a novel type of propolis and its chemical fractions on glucosyltransferases and on growth and adherence of mutans streptococci. Biol Pharm Bull 2003, 26:527-531.
13. Duarte S, Rosalen PL, Hayacibara MF, Cury JA, Bowen WH, Marquis RE, Rehder VL, Sartoratto A, Ikegaki M, Koo H: The influence of a novel propolis on mutans streptococci biofilms and caries development in rats. Arch Oral Biol 2006, 51:15-22.
14. Tanaka JCA, Silva CC, Dias Filho BP, Nakamura CV, Carvalho JE, Foglio MA: Constituintes quimicos de Luehea divaricata Mart (Tiliaceae). Quim Nova 2005, 28:834-837.
15. Hartman L, Lago RC: Rapid preparation of fatty acid methyl esters from lipids. Lab Pract 1973, 94:475-476.
16. Markham KR, Mitchell KA, Wilkins AL, Daldy JA, Lu Y: HPLC and GC-MS identification of the major organic constituents in New Zealand propolis. Phytochemistry 1996, 42:205-211.
17. Dilkas F, Bremner PD, Meyer J JM: Antibacterial activity of linoleic and oleic acids isolated from Helichrysum pedunculatum: a plant used during circumcision rites. Fitoterapia 2000, 71:450-452.
18. Wille JI, Kydonieus A: Palmitoleic acid isomer (C16:1 Delta 6) in human skin sebum is effective against gram-positive bacteria. Skin Pharmacol Appl Skin Physiol 2003, 16:176-187.
19. Yang CM, Lueddecke LO, Swanson BG, Davidson PM: Inhibition of microorganisms in salad dressing by sucrose and methylglucos fatty acid monooesters. J Food Process Preservat 2003, 27:285-298.
20. Hernández IM, Fernandez MC, Cuesta-Rubio O, Piccinelli AL, Rastrelli L, IJ: Polyisoprenylated benzophenone derivatives from Cuban propolis. J Nat Prod 2005, 68:931-934.
21. Tomas-Barberan FA, Garcia-Viguera C, Vit-Olivier P, Ferreres F, Tomas-Lorente F: Phytochemical evidence for the botanical origin of tropical propolis from Venezuela. Phytochemistry 1993, 34:191-196.
22. Cuesta Rubio O, Cuellar Cuellar A, Rojas N, Velez Castro H, Rastrelli L, Aquino R: A polyisoprenylated benzophenone from Cuban propolis. J Nat Prod 1999, 62:1013-1015.
23. Cuesta-Rubio O, Frontera-UrIBE BA, Ramirez-Apan T, Cárdenas J: Polyisoprenylated benzophenones in Cuban propolis: biological activity of nemorosone. Z Naturforsch [C] 2002, 57:372-378.
24. Trusheva B, Popova M, Bankova V, Simova S, Marucci MC, Miorin PL, Pasin FR, Tsvetkova I: Bioactive constituents of Brazilian red propolis. Evid Based Complement Alternat Med 2006, 3:249-254.
25. Bakana P, Claeys M, Totté J, Pi eters LA, Van Hoof L, Tamba-Vemba L, Berghé DA Van den, Vliezinck AJ: Structure and chemotherapeutical activity of a polyisoprenylated benzophenone from the stem bark of Garcinia huillensis. J Ethnopharmacol 1987, 21:75-84.
26. Hussain RA, Owgby AG, Parmoos P, Waterman PG: Kolanone, a novel polyisoprenylated benzophenone with antimicrobial properties from the fruit of Garcinia kola. Planta Med 1982, 44:78-81.
27. Iinuma M, Tosa H, Tanaka T, Kanamaru S, Asai F, Kobayashi Y, Miyauchi K, Shimano R: Antibacterial activity of some Garcinia benzophenone derivatives against methicillin-resistant Staphylococcus aureus. Biol Pharm Bull 1996, 19:311-314.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1472-6882/9/25/prepub